The largest Israeli investment fund in health and high technology (tech-med), called aMoon, announced today that it is looking for partners in Latin America to respond to the revolution in medical care in the world.
aMoon is a pioneering investment fund in the sector after raising so far 500 million dollars before closing the round of 2018, explained to Efe Dr. Yair Schindel, CEO and co-founder of aMoon with Marius Natch.
Schindel stressed that the world of health has fallen behind in the adoption of new technologies, but wants to match sectors such as accommodation (airbnb) or transport (Uber).
"Everything is based on technology and the administration of big data." Health and medicine follow the same path, only that we are talking about human lives, so the process of regulation and approval of new technologies in the sector is much more slow, "he added.
The new medical technology startups are those that are designing the future healthcare and new medicines with 3D systems that can model any component and genetically sequence a patient or a tumor.
"Before it was very expensive to do these processes but today for $ 300 you can get the genetic sequence of a patient," said Schindel, who considers it a priority to find Mexican, Brazilian and other Latin American companies that join the ongoing technological revolution.
aMoon has concentrated its investments in four companies. The first is DayTwo that develops software that provides personalized nutrition to allow people to lead healthier lives and maintain normal blood sugar levels.
DayTwo leverages its Gut Microbiome Platform to perform advanced genetic sequencing of intestinal microbiomes and big data analysis to predict the glycemic response of an individual based on intestinal microbiomes and other clinical parameters.
DayTwo translates this data into personal and practical information aimed primarily at preventing and treating metabolic diseases such as diabetes and obesity.
"Health systems have a large part of their millionaire expenses associated with metabolic diseases and their consequences, and with good nutrition the cost would go down in billions," says Schindel.
The second bet of aMoon is Nobio, involved in the development of antimicrobial particles that can be permanently integrated into multiple products and materials to inhibit the formation of biofilm on its surface.
A biofilm is a group of microorganisms in which cells adhere to each other and to the surface. The formation of biofilm can increase the resistance of bacteria against antibiotics, disinfectants and the immune response.
"We want to look for allies in Mexico and Brazil to introduce this technology and we want to start with the dental sector, dental hygiene is fundamental and bacteria are the main cause of oral infections," he added.
BiondVax is the third company in the portfolio of aMoon: a biopharmaceutical company in the clinical stage that is publicly traded and develops a universal vaccine against influenza.
Currently the influenza virus mutates every year and the vaccines, prepared based on the strain of the previous year, are relatively effective. They must also be inoculated one to two months before the infection season begins.
According to Yair Schindel, the technology and manipulation of big data has allowed BiondVax to analyze 40,000 strains of influenza from the last two decades and specifically identify the parts of the virus that do not change.
"It follows that if the virus keeps certain parts in its mutations it needs them, we have focused the research on nine of them, if the research is successful, we can offer a synthetic vaccine for influenza that lasts from 3 to 5 years, that can be inoculate in any season of the year and that does not need refrigeration, "he added.
The latest bet of aMoon is CartiHeal that develops a commercial implant, free of cells, for the treatment of cartilage and osteochondral defects.
Cartilage injuries affect millions of patients around the world, cause severe pain and disability and there are few solutions that do not involve major surgery.
The secret of this implant lies in the sea, in the coral reefs. By making two holes in the knee, the compound derived from the coral is implanted and in 48 hours the stimulation of this substance causes the cartilage to begin to regenerate.
"In three months the implant has been absorbed and the cartilage has been restored, and the knee of a 60-year-old man looks like a 20-year-old man's knee. We've seen it in tests in Europe," he said.